Company profile: Profound Medical
1.1 - Company Overview
Company description
- Provider of medical device solutions for MRI-guided ablation in prostate care, offering TULSA-PRO, a transurethral ultrasound ablation system under MRI guidance; Sonalleve, a HIFU therapy platform for non-invasive treatment of uterine fibroids and palliative bone metastases pain; and PRO-Talk, an educational platform with learning resources for physicians.
Products and services
- PRO-Talk: A physician-centric educational platform delivering learning resources for physicians, presenting educational content tailored to medical practitioners and supporting engagement with platform-provided learning materials
- Sonalleve: A HIFU-based therapy platform for non-invasive treatment of uterine fibroids and palliative treatment of bone metastases pain using High Intensity Focused Ultrasound energy
- TULSA-PRO: An MRI-guided therapeutic system employing transurethral ultrasound ablation to treat diseases of the prostate via urethral access under magnetic resonance imaging
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Profound Medical
Ikonisys
HQ: United States
Website
- Description: Provider of fully automated microscopy platforms and FISH-based diagnostic applications for early, accurate, non-invasive disease detection, including Ikoniscope20 for rare-cell detection and Ikoniscope20max with high-volume slide loading, plus oncoFISH solutions for bladder cancer (urine), HER2 status, cervical 3q26 gain in LSIL/ASCUS, and ALK gene rearrangements in non-small cell lung carcinoma.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Ikonisys company profile →
Oncocyte
HQ: United States
Website
- Description: Provider of blood-based and gene expression tests and biopharma services: DetermaCNI detects cancer progression early via cell-free DNA instability; DetermaIO assesses the tumor immune microenvironment to identify immunotherapy benefit; VitaGraft Kidney/Liver quantify donor-derived cell-free DNA to monitor transplant health and detect rejection; GraftAssure uses droplet digital PCR; and tissue- and blood-based biomarker-driven clinical trial support.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Oncocyte company profile →
Cellectis
HQ: France
Website
- Description: Provider of adoptive cancer immunotherapies, developing allogeneic CAR T candidates including UCART22 for r/r B-ALL, UCART123 targeting CD123 for AML, and UCART20x22 targeting CD20/CD22 for B-cell malignancies, plus TALEN gene editing and PulseAgile electroporation technologies.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Cellectis company profile →
Kiyatec
HQ: United States
Website
- Description: Provider of ex vivo 3D cell culture technology that uses a patient's own living tumor cells to create functional microtumor models for testing cancer therapies and predicting response. Offers 3D Predict Glioma and 3D Predict Oncology, patient-specific microtumor creation (up to 1,000) for drug testing, and a HIPAA-compliant portal delivering patient-specific reports within 7-10 days to aid treatment decisions.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Kiyatec company profile →
OnKure Therapeutics
HQ: United States
Website
- Description: Provider of next-generation oncology precision medicines targeting validated cancer drivers, developed by a clinical-stage biopharma.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full OnKure Therapeutics company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Profound Medical
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Profound Medical
2.2 - Growth funds investing in similar companies to Profound Medical
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Profound Medical
4.2 - Public trading comparable groups for Profound Medical
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →